Gonitro is a drug owned by G Pohl Boskamp Gmbh And Co Kg. It is protected by 1 US drug patent filed in 2016 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 11, 2032. Details of Gonitro's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9101592 | Stabilized granules containing glyceryl trinitrate |
Mar, 2032
(7 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Gonitro's patents.
Latest Legal Activities on Gonitro's Patents
Given below is the list of recent legal activities going on the following patents of Gonitro.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Jan, 2023 | US9101592 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 31 Jan, 2019 | US9101592 |
| Application ready for PDX access by participating foreign offices Critical | 31 Aug, 2015 | US9101592 |
| Recordation of Patent Grant Mailed Critical | 11 Aug, 2015 | US9101592 |
| Patent Issue Date Used in PTA Calculation Critical | 11 Aug, 2015 | US9101592 |
| Email Notification Critical | 23 Jul, 2015 | US9101592 |
| Issue Notification Mailed Critical | 22 Jul, 2015 | US9101592 |
| Dispatch to FDC | 10 Jul, 2015 | US9101592 |
| Application Is Considered Ready for Issue Critical | 10 Jul, 2015 | US9101592 |
| Issue Fee Payment Received Critical | 01 Jul, 2015 | US9101592 |
US patents provide insights into the exclusivity only within the United States, but Gonitro is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Gonitro's family patents as well as insights into ongoing legal events on those patents.
Gonitro's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Gonitro's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 11, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Gonitro Generic API suppliers:
Nitroglycerin is the generic name for the brand Gonitro. 26 different companies have already filed for the generic of Gonitro, with Mylan Technologies having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Gonitro's generic
Alternative Brands for Gonitro
There are several other brand drugs using the same active ingredient (Nitroglycerin) as Gonitro. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
| |
| Evus |
| |
| Pohl Boskamp |
| |
| Viatris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Nitroglycerin, Gonitro's active ingredient. Check the complete list of approved generic manufacturers for Gonitro
About Gonitro
Gonitro is a drug owned by G Pohl Boskamp Gmbh And Co Kg. Gonitro uses Nitroglycerin as an active ingredient. Gonitro was launched by Pohl Boskamp in 2016.
Approval Date:
Gonitro was approved by FDA for market use on 08 June, 2016.
Active Ingredient:
Gonitro uses Nitroglycerin as the active ingredient. Check out other Drugs and Companies using Nitroglycerin ingredient
Dosage:
Gonitro is available in powder form for sublingual use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.4MG/PACKET | POWDER | Discontinued | SUBLINGUAL |